Acer Therapeutics (OTCPK:ACER) - Cotización, noticias y análisis

Resumen de acción ACER

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases.

Acerca de la empresa

ACER fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los beneficios de 66.22%

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Patrimonio neto negativo

Alta volatilidad del precio de la acción en los últimos 3 meses

Tiene menos de 1 año de cash runway

+ 2 riesgos adicionales

Competidores de Acer Therapeutics Inc.

TherapeuticsMD

NasdaqGS:TXMD

US$21.7m

DURECT

NasdaqCM:DRRX

US$30.0m

Lipocine

NasdaqCM:LPCN

US$25.2m

Sol-Gel Technologies

NasdaqGM:SLGL

US$21.8m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Acer Therapeutics
Historical stock prices
Current Share Price	US$0.80
52 Week High	US$4.56
52 Week Low	US$0.55
Beta	0.44
1 Month Change	-2.73%
3 Month Change	21.88%
1 Year Change	-30.04%
3 Year Change	-70.42%
5 Year Change	-96.75%
Change since IPO	-91.99%

Noticias y actualizaciones recientes

Recent updates

Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment

Oct 05

Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU

Aug 12

FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy

Jul 28

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

Feb 25

Acer Therapeutics completes enrollment in ACER-001 bioequivalence trial for urea cycle disorders

Dec 22

Rentabilidad de los accionistas

	ACER	US Pharmaceuticals	Mercado US
7D	-5.4%	3.0%	0.3%
1Y	-30.0%	12.0%	24.2%

Rentabilidad vs. Industria: ACER obtuvo unos resultados inferiores a los del sector US Pharmaceuticals , que el año pasado arrojó un rendimiento del 9.7%.

Rentabilidad vs. Mercado: ACER obtuvo unos resultados inferiores a los del mercado US, que fue del 19.3% el año pasado.

Volatilidad de los precios

Is ACER's price volatile compared to industry and market?
ACER volatility
ACER Average Weekly Movement	32.3%
Pharmaceuticals Industry Average Movement	9.9%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de ACER ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ACER ha aumentado de 23% a 32% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1991	30	Chris Schelling	www.acertx.com

Resumen de fundamentos de Acer Therapeutics Inc.

¿Cómo se comparan los beneficios e ingresos de Acer Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de ACER
Capitalización bursátil	US$19.68m
Beneficios(TTM)	-US$38.76m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-0.5x

Ratio precio-beneficio (PE)

¿Está ACER sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ACER
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$38.76m
Beneficios	-US$38.76m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.58
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	-96.4%

¿Cómo se ha desempeñado ACER a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción ACER

Recompensas

Análisis de riesgos

Competidores de Acer Therapeutics Inc.

NasdaqGS:TXMD

US$21.7m

NasdaqCM:DRRX

US$30.0m

NasdaqCM:LPCN

US$25.2m

NasdaqGM:SLGL

US$21.8m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Acer Therapeutics Inc. Files Form 15

Acer Therapeutics Inc. Announces Executive Changes

Nasdaq to Delist the Securities of Acer Therapeutics

Acer Therapeutics Inc. announced delayed 10-Q filing

Acer Therapeutics Inc. announced delayed 10-Q filing

Acer Therapeutics Inc.(OTCPK:ACER) dropped from S&P TMI Index

Recent updates

Acer Therapeutics Inc. Files Form 15

Acer Therapeutics Inc. Announces Executive Changes

Nasdaq to Delist the Securities of Acer Therapeutics

Acer Therapeutics Inc. announced delayed 10-Q filing

Acer Therapeutics Inc. announced delayed 10-Q filing

Acer Therapeutics Inc.(OTCPK:ACER) dropped from S&P TMI Index

Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) entered into definitive Agreement to acquire Acer Therapeutics Inc. (NasdaqCM:ACER) for $91 million.

Acer Therapeutics Receives a Letter from Nasdaq Indicating the Company Is Not in Compliance with the $1.00 Minimum Bid Price Requirement Set in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Acer Therapeutics Inc. Receives Non-Compliance Notice From Nasdaq

Acer Therapeutics Announces Full Enrollment of Phase 2A Trial of Acer-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Acer Therapeutics Inc. Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate

Acer Therapeutics Compliant with All Nasdaq Listing Criteria

Acer Therapeutics Inc. announced that it has received $1.5 million in funding

Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.23 loss in 3Q 2021)

Insufficient new directors

Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)

Acer Therapeutics Inc. Announces Receipt of Notice of Allowance of US Patent Application Covering Kit Comprising Phenylbutyrate and Sodium Benzoate

Acer Therapeutics Inc. Announces Expansion of Acer-801 (Osanetant) Development Indications to Include Post-Traumatic Stress Disorder

Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment

First half 2022 earnings released: US$0.80 loss per share (vs US$0.54 loss in 1H 2021)

RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. Announce That the European Commission Has Granted Orphan Drug Designation for Acer-001 in Maple Syrup Urine Disease

Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy

Acer resubmits U.S. marketing application for urea cycle disorder therapy

Acer Therapeutics Inc. Resubmittes the ACER-001 New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders

Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome

Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application for ACER-001

Acer Therapeutics Not Yet Received Decision from the U.S. Food and Drug Administration on ACER-001

Acer Therapeutics Receives a Letter from the Listing Qualifications Department Staff of the Nasdaq Stock Market Regarding Minimum Market Value of Listed Securities

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Acer Therapeutics Inc. Provides an Update on the Recent Corporate Developments

Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients

Acer Therapeutics Inc. and Relief Therapeutics Holding AG Announce Presentation of Acer-001 Data At the Genetic Metabolic Dieticians International Conference

Insufficient new directors

Acer Therapeutics Inc., Annual General Meeting, May 20, 2022

Acer Therapeutics Inc. and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting

Acer Therapeutics’ EDSIVO Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome

Acer Therapeutics Regains Compliance with Nasdaq Listing Standard

Acer Therapeutics Enrolls First Patient in Its Phase 2A Clinical Trial of Acer-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Consensus revenue estimates fall by 29%

Acer Therapeutics Inc. Announces Appointment of Adrian Quartel as Chief Medical Officer

Companies Like Acer Therapeutics (NASDAQ:ACER) Can Afford To Invest In Growth

No longer forecast to breakeven

Acer Therapeutics Inc. Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms

Acer Therapeutics: Deriving Value By Developing Therapies For Rare Diseases

Consensus forecasts updated

Acer Therapeutics Plans Clinical Trial for Edsivo Following Type B FDA Meeting

Acer Expands Its Predator Gaming Portfolio with Three New HDR Monitors

Acer Therapeutics Plans NDA Submission for Acer-001 in Third Quarter 2021 Following Pre-NDA Meeting with FDA

Consensus revenue estimates increase to US$8.00m

We're Not Very Worried About Acer Therapeutics' (NASDAQ:ACER) Cash Burn Rate

Acer Therapeutics Inc. Announces Update on Settlement of Derivative Suits

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

Acer Therapeutics Inc. Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions

Relief Therapeutics and Acer Therapeutics Sign Option Agreement to Pursue a Potential Collaboration and License Arrangement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

New 90-day high: US$3.85

Acer Therapeutics completes enrollment in ACER-001 bioequivalence trial for urea cycle disorders